En español

NIDA Notes Articles: Buprenorphine

NIDA Notes Category Graphic

Dual Regimen Aims To Shorten Medication-Assisted Therapy

May 2016

Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.

NIDA Notes Category Graphic

ED-Initiated Buprenorphine Outperforms Referral or SBIRT for ED Patients With Opioid Addiction

January 2016

Emergency department visits present prime opportunities to identify people with opioid addiction and provide them with onsite initiation of treatment with buprenorphine/naloxone.

NIDA Notes Category Graphic

Long-Term Follow-Up of Medication-Assisted Treatment for Addiction to Pain Relievers Yields “Cause for Optimism”

November 2015

In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.

NIDA Notes Category Graphic

Study Points to Individualized Therapy for Opioid Addiction

February 2015

Trial participants who were addicted to opioid painkillers and did not inject drugs stayed in treatment longer and achieved better outcomes than those who were addicted to heroin or injected drugs.

NIDA Notes Category Graphic

Patients Addicted to Opioid Painkillers Achieve Good Results With Outpatient Detoxification

February 2015

A significant portion of individuals who are addicted to opioid painkillers may initiate and maintain abstinence with a brief but intensive outpatient detoxification treatment followed by opioid antagonist therapy using naltrexone.

NIDA Notes Category Graphic

Gene Variants Reduce Opioid Risks

June 2014

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

NIDA Notes Category Graphic

Dr. Evan D. Kharasch Joins the Institute of Medicine

December 2013

Dr. Kharasch is a NIDA-funded researcher known for a broad range of research into how drugs are metabolized in the body.

NIDA Notes Category Graphic

Medications That Treat Opioid Addiction Do Not Impair Liver Health

December 2013

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

NIDA Notes Category Graphic

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

September 2013

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

NIDA Notes Category Graphic

Q & A: Dr. Redonna Chandler

April 2013

The chief of NIDA's Services Research Branch talks about drug abuse treatment within the criminal justice system, and assesses the challenges facing drug abuse treatment overall in the United States.


NIDA Notes


Drug Topics

Drugs of Abuse

Population Groups

Related Topics